Synergy Pharmaceuticals Inc. today announced the start of its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide, its lead uroguanylin analog and once-daily oral treatment, in adult patients with chronic idiopathic constipation .
http://ift.tt/1m0AkRB
http://ift.tt/1m0AkRB
No comments:
Post a Comment